PATENT CLAIM ANALYSIS

Application Number: 16292011
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-06
Patent Classification: ["514", "364000"]

Abstract:
The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

Claim (Index 80):
The method of  claim 66 , wherein the HDAC inhibitor and/or the GSK3\u03b2 inhibitor is administered for about 1-10 days, 10-20 days, 20-30 days, 30-40 days, 40-50 days, 50-60 days, 60-70 days, 70-80 days, 80-90 days, 90-100 days, 1-6 months, 6-12 months, or 1-5 years.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 99.0
- Lexical Diversity: 1.93878
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15317559', '16012536', '14783344', '14506889', '12022977']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.774489997855681
- 35 USC 102 Novelty (BERT): 0.5811702729224407
- Combined Prediction Score: 0.755158025362357
- Mean Citation Score: 372.964488
- Max Citation Score: 610.5238
- Similarity Product: 341.40217289371486

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test